The CPAP Compliance Report 2026

CPAP came to market in the early 1980s. Forty years later, the adherence number that defines treatment success has barely moved. Sleep medicine has improved the masks, the machines, and the compliance reporting, but not the fundamental "will this patient still be using it in a year?" question.

• Rotenberg and colleagues' analysis of 20 years of CPAP adherence data concluded simply: "no clinically significant improvement in CPAP adherence was seen" across two decades of effort (PMC 4992257).
• CMS-defined adherence (≥4 hours/night on at least 70% of nights over a 30-day window) sits at roughly 43% across 2000–2016 — the most-cited figure in the literature (PMC 7803941).
• More recent cohorts hover in the same range. A 2024 MDPI review reported 61.8% compliant / 38.2% non-compliant at the same threshold — slightly better, but still leaving roughly four in ten patients undertreated (MDPI 2024).
• The four-hour threshold itself is contested. There is evidence that longer nightly use is required to fully reduce cardiovascular event risk; the "compliant" label, in other words, may be set too low.

Why hasn't the curve moved? The honest answer in the literature is that CPAP adherence isn't a device problem — it's a behavioural and environmental problem. The mask hasn't changed substantially in two decades because the obstacle is upstream of it.

Patient surveys, qualitative studies, and clinician reports cluster around roughly ten recurring reasons. Some are device-fixable. Some are not.

• 1. Mask discomfort and skin irritation. The single most reported reason patients stop using CPAP. Pressure marks across the nose bridge, leaks at the cheeks, and contact dermatitis from silicone or fabric are all common and rarely resolved on the first mask fit. See long-term compliance review, PMC 2679572.
• 2. Pressure feels wrong (too high, too low, or fluctuating). Patients describe the airflow as suffocating, blasting them awake, or so weak it feels pointless. Auto-titrating (APAP) devices help some patients but introduce their own variability that bothers others.
• 3. Claustrophobia and restriction. A subset of patients can't tolerate the mask on their face long enough to fall asleep. Anxiety on initiation predicts much of the abandonment that shows up in the first month.
• 4. Dry mouth, nasal congestion, and sinus problems. Humidifiers help but don’t fully resolve airway dryness for everyone. Patients with chronic rhinitis or septal deviation are particularly likely to find CPAP unworkable on top of their baseline nasal symptoms. Nasal discomfort cited frequently in patient surveys (PMC 2679572).
• 5. Cleaning, maintenance, and supply hassle. Daily wiping of cushions, weekly tubing cleans, monthly filter changes, and the supply-prescription loop becomes the visible cost of treatment in a way the actual OSA never quite does.
• 6. Aerophagia (swallowing air) and bloating. Air pressure intended for the airway sometimes ends up in the stomach. Adjusting position, pressure, and ramp settings helps, but for some patients this becomes the deal-breaker.
• 7. Travel and lifestyle disruption. Hotel power outlets, TSA conversations, dependence on a single device, partner sleep environment changes — the daily logistics add up. Travel-friendly machines help, but the social friction is real.
• 8. Insurance and durable medical equipment friction. CMS adherence reporting periods mean some patients have to demonstrate use in a defined window or lose insurance coverage. The pressure to comply turns into resentment, then into giving up entirely.
• 9. Lack of perceived benefit. Patients who don’t feel dramatically better in the first few weeks are statistically more likely to abandon CPAP. Sleep apnea’s slow-burning consequences (cardiovascular, cognitive) don’t register in week one.
• 10. Insufficient clinical follow-up. Initial fitting, then nothing for 90 days, is still a common pattern. The literature now strongly favours earlier follow-up — within 1–3 weeks of starting — to catch fixable problems while patients still want to fix them. Pulmonology Advisor, 2024.

Six of the ten are mechanical and clinician-addressable: mask fit, pressure tuning, humidification, aerophagia management, supply logistics, and follow-up cadence. The other four — claustrophobia, perceived-benefit deficit, insurance friction, and travel — are harder, and they don't go away with a different mask.

One of the most striking findings in the adherence literature is how early the trajectory is set. Patients who struggle in the first 7–12 days are the ones who quit at 5 years, with risk ratios that don't shrink with more clinical effort downstream.

• Patients with poor compliance at 12 days had a 5.8× risk (95% CI 2.11–15.95) of abandoning CPAP at 5 years compared with patients who were adherent at 12 days (Tanahashi et al., Sleep Med 2013).
• Patients with poor compliance at 6 months had a 14.5× risk (95% CI 4.14–51.02) of long-term abandonment.
• Machine-log data from the first week alone can predict downstream non-adherence with high accuracy (Sci Reports, 2022).
• The implication is clinical and time-sensitive: the recommended first follow-up window is now 1–3 weeks, not the legacy 30–90 days. Earlier outreach catches fixable problems before patients form a permanent "this isn't for me" frame (Pulmonology Advisor, 2024).

Adherence isn’t random. Demographic, clinical, and psychological predictors all show up in the literature. The patterns matter both for triaging clinical attention and for understanding which patients deserve a different first-line option.

• Age: older patients (60+) tend to have higher adherence than younger patients, partly because their daytime symptoms are more disruptive and partly because they're more likely to have established medical routines (PMC 7803941).
• Sex: men and women show different adherence patterns, with some studies finding women have higher early dropout related to mask fit issues and claustrophobia.
• Severity: patients with severe OSA (AHI ≥ 30) and high daytime sleepiness adhere more reliably — they feel the difference quickly.
• Race and ethnicity: Hispanic patients with OSA had 50% higher odds of being untreated (AOR 1.50, 95% CI [1.02, 2.21]) compared with non-Hispanic Whites (Sleep 2025 supplement). Sleep apnea is "underdiagnosed and undertreated among ethnic minorities" (MDPI 2024).
• Mental health: patients with anxiety or PTSD show substantially higher CPAP dropout in the first 90 days, often before clinicians realise the issue is anxiety rather than equipment.

Non-adherence isn’t a neutral outcome — the patient just isn’t treated. It propagates into downstream healthcare utilisation in measurable ways.

• Non-adherence is significantly associated with higher 30-day hospital readmission rates (AASM 2024 review). Failure to treat OSA effectively shows up as recurrent admissions for the cardiovascular and metabolic comorbidities OSA accelerates.
• The American Heart Association's 2021 scientific statement reports OSA prevalence of 40–80% in patients with hypertension, heart failure, coronary artery disease, AF, and stroke (AHA Circulation).
• Untreated OSA is also a risk factor for cognitive decline, with longitudinal data linking it to elevated dementia risk, particularly in older women (Michigan Medicine).
• The annual US economic burden from untreated OSA is estimated at $202.9 billion, with most of that figure attributable to non-adherent and undiagnosed patients (ResMed Sleep Institute).

"Alternative" doesn't mean "worse." For CPAP-intolerant patients, an alternative that gets used nightly often outperforms a gold-standard treatment that sits in a drawer. Below: the realistic menu in 2026, with effect-size and adherence figures where the literature is firm.

AHI reduction and adherence figures are drawn from the sources cited throughout this report and the treatments cluster of the broader stats report. Cost figures synthesise typical US 2025–26 ranges.

For most of CPAP’s history, "treatment" and "CPAP" were essentially synonymous. That changed in a six-month window between September 2024 and early 2025.

• September 2024 — Apple Watch sleep apnea notifications. The FDA cleared the Sleep Apnea Notification Feature for Apple Watch Series 9, Series 10, and Ultra 2. For the first time, a screen-positive result can come from a wrist-worn device instead of a primary-care referral chain (CNBC).
• December 2024 — Zepbound (tirzepatide) approved for OSA. The first prescription drug specifically for sleep apnea in adults with obesity. Weekly injection rather than nightly device tolerance, which structurally addresses the adherence problem (Eli Lilly press release).
• Hypoglossal nerve stimulation maturing. Inspire's five-year outcomes data shows ~75% surgical success and around 81% nightly use — meaningfully higher adherence than CPAP for eligible candidates (HGNS long-term outcomes).
• App-delivered myofunctional therapy. Smartphone delivery of oropharyngeal exercises is now research-supported (PMC 6340784) and gives clinicians a CPAP-adjunct option that doesn't require a device on the face. See guided myofunctional therapy for the protocol.

These aren't replacements for CPAP — they're additions to a treatment menu that, for forty years, was effectively a single dish. The structural question for the next decade isn't whether the 43% figure improves. It's whether the 60% of patients who don't tolerate CPAP now have somewhere clinically useful to go.

Adherence is built in the first three weeks of therapy and protected for the next year. The literature now points to a small handful of high-leverage clinician moves.

• Move first follow-up to week 1–3. Patients with a structured early check-in have meaningfully better adherence at one year. The cost is low and the predictive power is enormous (Pulmonology Advisor).
• Use machine-log data actively. Modern CPAP devices report adherence patterns to the cloud. A patient who isn’t using the machine in week 1 doesn’t need a 90-day follow-up — they need a phone call.
• Pre-screen for anxiety and PTSD. A short questionnaire at initiation flags patients who may need a different approach to mask desensitisation, or who may be better candidates for an oral appliance from the start.
• Open the door to alternatives sooner. A patient who has tried CPAP for three months and still hates it is not failing therapy — they are providing data that should change the plan. Many CPAP non-adherent patients qualify for oral appliances, myofunctional therapy, Inspire, or tirzepatide, and those conversations are happening too late.

If you’ve been issued a CPAP and you’re reading this trying to figure out whether to keep going, the literature is clear on a few things.

• Push hard in the first two weeks. The first ten to fourteen nights set the trajectory. If something is wrong — pressure, mask fit, dry mouth — tell your clinician within a week, not after a month of toughing it out.
• Don’t treat the initial mask as the final mask. Most patients end up on the second or third mask they try. Pillow masks, full-face masks, and different cushion sizes solve very different problems.
• Ask about alternatives if it isn’t working at month three. Oral appliances, myofunctional therapy, weight-loss interventions including tirzepatide, Inspire (for the right candidates), and combination approaches all exist. They were rarely discussed before 2020. They should be discussed now.
• If your snoring + sleep apnea is mild-to-moderate, consider whether a daily airway exercise routine is a fit alongside or instead of CPAP. The evidence is strongest for oropharyngeal exercises and myofunctional therapy, both of which we cover in detail elsewhere on this site.